Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of LBH589, a Novel Histone Deacetylase Inhibitor, in Relapsed and Refractory Adult Patients With Acute Leukemia (AL) or in Newly Diagnosed Patients Over the Age of 60

NCT00723203 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT00723203
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00723203 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of LBH589, a Novel Histone Deacetylase Inhibitor, in Relapsed and Refractory Adult Patients With Acute Leukemia (AL) or in Newly Diagnosed Patients Over the Age of 60
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2008
Completion date
September 30, 2010
Enrollment
16 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia